1-2 of 2
Ephraim P. Hochberg
Close
Sort by
Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Clinical Trials & Observations
Inhye E. Ahn, Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker, Robert Black, Josie Montegaard, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A. Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer Crombie, David C. Fisher, Ann S. LaCasce, Jon Arnason, Ephraim P. Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (4): 832–841.
https://doi.org/10.1182/bloodadvances.2023011574
Published: 2024
Includes: Supplemental data
Journal Articles

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Clinical Trials & Observations
J. Erika Haydu, Jenny S. Maron, Robert A. Redd, Kathleen M. E. Gallagher, Stephanie Fischinger, Jeffrey A. Barnes, Ephraim P. Hochberg, P. Connor Johnson, R. W. Takvorian, Katelin Katsis, Daneal Portman, Jade Ruiters, Sidney Sechio, Mary Devlin, Connor Regan, Kimberly G. Blumenthal, Aleena Banerji, Allen D. Judd, Krista J. Scorsune, Brianne M. McGree, Maryanne M. Sherburne, Julia M. Lynch, James I. Weitzman, Matthew Lei, Camille N. Kotton, Anand S. Dighe, Marcela V. Maus, Galit Alter, Jeremy S. Abramson, Jacob D. Soumerai
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1671–1683.
https://doi.org/10.1182/bloodadvances.2021006627
Published: 2022
Includes: Supplemental data